Skip to search boxSkip to navigationSkip to main content

HPV as a model for the development of prophylactic and therapeutic cancer vaccines

  • Raed N. Samara
    ,
  • Samir N. Khleif
  • National Institutes of Health
Scholary Output:
Contribution to journal
Review article
Research
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

HPV has been linked to many human malignancies and, as such, represents a major public health crisis. The understanding of HPV biology, however, has helped tremendously in developing prophylactic vaccines, which should help in decreasing mortality due to HPV infections. Understanding HPV biology has allowed researchers to use the virus as a model for the development of not only prophylactic vaccines, but also therapeutic ones. The advantages of HPV as a model stem from the limited number of proteins encoded by the HPV genome that can be targeted by vaccines, and also from the restricted expression of certain viral proteins during different stages of infection. In this review, we discuss how HPV can be used as a model for the development of both prophylactic and therapeutic vaccines.

Publication Information

Output type

Scholary Output:
Contribution to journal
Review article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 766-773 (8 pages)

Journal (Volume, Issue Number)

Current Molecular Medicine (Volume 9, Issue 6)

Publication milestones

  • Published - 08/2009

Publication status

Published - 08/2009

ISSN

1566-5240

Publication IDs

  • Scopus: 70350525547
  • PubMed: 19689303

Publication metrics

Metrics

Scopus
citations
SciVal
citations
4
SciVal
FWCI
0.04
SciVal
Author count
2
SciVal
Paper percentile
47
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Citation count
4
Captures
6